Evidence map›Paper›PMID 41153044›Full record

ArticleClinical epigenetics2025

NSUN2 promotes leukemogenesis by ferritin heavy chain 1-mediated anti-ferroptosis and enhancing global protein synthesis in an m

Yigang Yuan, Min Li, Xuanyu Yu, Chen Meng, Shirui Yu, Xinyao Chen, Shixin Zhang, Liuzhi Shi, Xiaoyi Qin, Ziyang Huang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yigang Yuan *Medical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Min Li *Medical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Xuanyu Yu *Medical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Chen MengMedical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Shirui YuMedical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Xinyao ChenMedical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Shixin ZhangMedical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Liuzhi ShiDepartment of Clinical Laboratory, The First Affiliated Hospital of Wenzhou Medical University, 1 Xuefubei Street, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Xiaoyi QinDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Ziyang HuangDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Chongyun XingDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Shanhu QianDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China.
Bin ZhouMedical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China. zhoubin@wzhospital.cn.
Shenmeng GaoMedical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, 1 Xuefubei Street, Wenzhou, Zhejiang Province, China. gaoshenmeng77@wzhospital.cn.

Funding

Discipline Cluster of Oncology of Wenzhou Medical University of China z2-2023021the National Natural Science Foundation of China 81971991Zhejiang Provincial Natural Science Foundation of China LY23H080003
6 · The paper itself

Abstract

backgroundNOP2/Sun RNA methyltransferase family member 2 (NSUN2) catalyzes 5-methylcytosine (m

methodsLineage-negative progenitor cells from Nsun2 knockout (Δ/Δ) and wild-type (fl/fl) mice were used to generate BCR-ABL (P190)-driven murine B-ALL model. Furthermore, RNA sequencing (RNA-seq) was performed to identify NSUN2 targets. Cell proliferation, apoptosis, and colony formation, and global protein synthesis were measured in B-ALL cells with NSUN2 deficiency.

resultsHere, we found that NSUN2 expression was significantly higher in bone marrow (BM) cells from B-ALL patients than normal controls (NCs). Knockdown of NSUN2 reduced m

conclusionsOur results demonstrate that NSUN2 facilitates leukemogenesis by increasing FTH1 expression and enhancing global protein synthesis in an m

Indexed as

ApoferritinsMethyltransferasesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma5-MethylcytosineAnimalsApoptosisDisease Models, AnimalFerritinsHumansMiceMice, KnockoutOxidoreductasesProtein Biosynthesis5-MethylcytosineApoferritinsFerritinsFTH1 protein, humanMethyltransferasesOxidoreductasesFerroptosisFTH1m5C modificationsNSUN2

Identifiers

PMID41153044
PMCPMC12570736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.